3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Neoplasm Metastasis
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Head and Neck Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Adenocarcinoma Of Esophagus
1
Interventions
Fluorouracil
7
Oxaliplatin
5
Cisplatin
4
tremelimumab
3
durvalumab
3
Radiotherapy
3
Paclitaxel
3
Leucovorin
3
Surgical Procedures, Operative
2
Radiation
2
Docetaxel
2
Cetuximab
2
Carboplatin
2
Capecitabine
2
zanidatamab
1
trastuzumab deruxtecan
1
rucaparib
1
oblimersen
1
monalizumab
1
cabozantinib
1
benzamide
1
Trastuzumab
1
Taxes
1
Ramucirumab
1
Nivolumab
1
Neoadjuvant Therapy
1
Microarray Analysis
1
Metabolic Networks and Pathways
1
LY2940680
1
Immunohistochemistry
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Adenocarcinoma Of Esophagus
×
monalizumab
×
Clear all
NCT03307941
2017-12-19
ARTEMIS-Eso
Jules Bordet Institute
Phase 1/2
Withdrawn